5-甲氧基-N,N-二异丙基色胺 | 69496-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-甲氧基-N,N-二异丙基色胺
• 英文名称: [2-(5-methoxy-1H-indol-3-yl)ethyl]dipropylamine
• 英文别名: 5-methoxy-N,N-di-n-propyltryptamine；5-methoxy-N,N-dipropyltryptamine；5-MeO-DPT；<2-(5-Methoxy-indol-3-yl)-ethyl>-dipropyl-amin；[2-(5-methoxy-indol-3-yl)-ethyl]-dipropyl-amine；N,N-di-n-propyl-5-methoxytryptamine；5-Methoxydipropyltryptamine；N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
• CAS: 69496-75-9
• 化学式: C₁₇H₂₆N₂O
• 分子量: 274.406
• InChiKey: PNHPVNBKLQWBKH-UHFFFAOYSA-N

物化性质

• 沸点：
  421.9±35.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  28.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  碘甲烷 、 5-甲氧基-N,N-二异丙基色胺 以 四氢呋喃 为溶剂， 生成 [2-(5-methoxy-1H-indol-3-yl)ethyl](methyl)dipropylazanium iodide
  参考文献：
  名称：

  TRYPTAMINE DERIVATIVES

  摘要：

  This disclosure relates to bis(2-(lH-indol-3-yl)ethan-l-aminium) butanedioate (tryptammonium succinate), crystalline tryptammonium succinate, 2-(lH-indol-3-yl)ethan-l-aminium acetate (tryptammonium acetate), crystalline tryptammonium acetate, 2-(5-methoxy-lH-indol-3- yl)ethanamine acetate (5-methoxytryptammonium acetate or 5-MeO-T acetate), crystalline 5-MeO-T acetate, trimethyl[2-(7-methyl-lH-indol-3-yl)ethyl]azanium iodide (7-methyl-A/,A/,/V- trimethyltryptammonium iodide or 7-Me-TMT iodide), crystalline 7-Me-TMT iodide, triethyl [2-(7- methyl-lH-indol-3-yl)ethyl]azanium iodide (7-methyl-/V,A/,A/-triethyltryptammonium iodide or 7-Me- TET iodide), crystalline 7-Me-TET iodide, [2-(5-methoxy-lH-indol-3-yl)ethyl](methyl)dipropylazanium iodide (5-methoxy-/V-methyl-A/,A/-di-n-propyltryptammonium iodide or 5-MeO-MDPT iodide), crystalline 5-MeO-MDPT iodide, and specific crystalline forms thereof, including crystalline form 1 of tryptammonium succinate, crystalline form 1 of tryptammonium acetate, crystalline form 1 of 5- MeO-T acetate, crystalline form 1 of 7-Me-TMT iodide, crystalline form 1 of 7-Me-TET iodide, and crystalline form 1 of 5-MeO-MDPT iodide; to compositions containing the same; and to methods of treatment using them.

  公开号：

  WO2024040158A2

文献信息

• Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion
  申请人：ELI LILLY AND COMPANY

  公开号：EP0455510B1

  公开（公告）日：1996-11-27
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20210069170A1

  公开（公告）日：2021-03-11

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• US5096908A
  申请人：——

  公开号：US5096908A

  公开（公告）日：1992-03-17